Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor ...

Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...

Pfizer (PFE) closed the latest trading day at $26.75, indicating a -0.41% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Attorney General Mike Hilgers announced Tuesday, Nebraska has joined the United States, 37 other states, and Puerto Rico to ...

Rights Aug 02, 2023 Aug 02, 2023 Feb 08, 2023 Rights ratio: 5 share for every 46 held at a price of Rs 81.0 ...